Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioChaperone Lispro U-100 vs U-200 PK/PD in Healthy Subjects
NCT02529293Phase 1Completed
- Sponsor
- Adocia
- Start
- Aug 2015
- Primary completion
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BioChaperone Lispro in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Adocia. Primary endpoints: Area Under the Curve for Insulin Lispro (0-inf) at 8 hours and Maximum Concentration of Insulin Lispro at 8 hours. Started Aug 2015; status: completed.
02
Drugs
BioChaperone Lispro
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02529293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529293.